Cronos Group Inc.

Cronos reported consolidated net revenue of $53 million, up 58% year over year. Gross profit was $28.5 million, up 96% year over year from Q2 2025, and adjusted EBITDA was a record $13.1 million, up $11.4 million year over year. Total operating expenses were $21 million, up $1.2 million year over year, including about $500,000 of transaction costs related to the pending CanAdelaar acquisition. The company ended the quarter with $827 million in cash, cash equivalents, short-term investments, and non-current interest-bearing deposits, up $5 million from Q1 2026, driven by $24 million of positive cash flow from operations, partially offset by $60 million of share repurchases and $2 million of CapEx. Management did not give explicit next-quarter revenue or EPS guidance; it reiterated confidence in continued growth, expected the CanAdelaar acquisition to close in the second half of 2026, and said it expects gross margin can vary quarter to quarter based on seasonality, mix, volumes, and pricing.

Mike Gorenstein framed the quarter as a broad-based win, saying Cronos achieved records across net revenue, gross profit, and adjusted EBITDA as its “borderless product strategy” gained momentum. He highlighted strong execution in Israel, Canada, and other international markets, plus improving supply and manufacturing at GrowCo, Stayner, and Israel. He also sounded constructive on the CanAdelaar acquisition and said Cronos remains committed to capital returns through buybacks while keeping balance-sheet flexibility.

Anna Shlimak said revenue growth was primarily driven by higher cannabis flower sales in Israel, Canada, and Germany, plus higher cannabis extract sales in Canada. She pointed to gross profit of $28.5 million, helped by higher average selling prices, a mix shift toward Israel and other no-excise-tax markets, higher volumes, and better overhead absorption from stronger yields and seasonally favorable growing conditions. She also noted operating expenses of $21 million, up $1.2 million year over year, with $500,000 tied to CanAdelaar transaction costs, and emphasized the $827 million balance sheet position alongside $24 million of operating cash flow and $60 million of buybacks.

Analysts focused on what drove the outperformance, Spinach’s ability to cross formats and potentially cross borders, and whether stronger supply from GrowCo was supporting share gains. Management said PUFFERZ momentum, better yields, more supply, and improved execution across facilities were all contributing, while Spinach is being built as a product-led brand that could translate into new markets like the Netherlands. Questions also covered Germany, Israeli supply/import flexibility, and the U.S. state-by-state scenario; Gorenstein said Cronos would likely favor borderless products and IP over heavy infrastructure if the U.S. remains fragmented, and he said the company does not need to use stock as currency or raise capital.